0001209191-17-019994.txt : 20170310 0001209191-17-019994.hdr.sgml : 20170310 20170310200532 ACCESSION NUMBER: 0001209191-17-019994 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170309 FILED AS OF DATE: 20170310 DATE AS OF CHANGE: 20170310 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ADURO BIOTECH, INC. CENTRAL INDEX KEY: 0001435049 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 740 HEINZ AVENUE CITY: BERKELEY STATE: CA ZIP: 94710 BUSINESS PHONE: 510-848-4400 MAIL ADDRESS: STREET 1: 740 HEINZ AVENUE CITY: BERKELEY STATE: CA ZIP: 94710 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH DATE OF NAME CHANGE: 20080514 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brockstedt Dirk G. CENTRAL INDEX KEY: 0001635616 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37345 FILM NUMBER: 17683559 MAIL ADDRESS: STREET 1: C/O ADURO BIOTECH, INC. STREET 2: 740 HEINZ AVENUE CITY: BERKELEY STATE: CA ZIP: 94710 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-03-09 0 0001435049 ADURO BIOTECH, INC. ADRO 0001635616 Brockstedt Dirk G. C/O ADURO BIOTECH, INC. 740 HEINZ AVENUE BERKELEY CA 94710 0 1 0 0 EVP of Research and Dev. Common Stock 2017-03-09 4 M 0 8000 0.45 A 57300 D Common Stock 2017-03-09 4 S 0 8000 11.0001 D 49300 D Stock Option (Right to Buy) 0.45 2017-03-09 4 M 0 8000 0.00 D 2020-03-18 Common Stock 8000 35195 D The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2016. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.85 to $11.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The shares subject to the Option are fully vested and immediately exercisable. /s/ Jennifer Lew, Attorney-in-Fact 2017-03-10